Product image of Iluvien (Fluocinolone Acetonide) supplied by GNH India

Iluvien

Active Ingredient:
Fluocinolone Acetonide
Origin:
EU

Iluvien (Fluocinolone Acetonide)

Fluocinolone acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal sustained‑release implant for intravitreal use. It delivers continuous anti‑inflammatory therapy to the retina for up to 36 months, reducing the need for repeated injections, and is indicated for diabetic macular edema in adult patients.

GNH India supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established export capabilities to the European Union and other regulated markets, and adhering to stringent quality standards.

Manufacturer / TM Owner

Alimera Sciences Europe Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Iluvien (fluocinolone acetonide) is used to manage ocular inflammatory conditions, specifically diabetic macular edema, by delivering corticosteroid therapy directly to the retina.

  • Diabetic macular edema: reduces retinal swelling and stabilizes visual acuity.
  • Chronic diabetic macular edema: provides sustained drug release, decreasing need for repeat injections.
  • Refractory diabetic macular edema: offers an alternative when other therapies are insufficient.

How It Works

  • Fluocinolone acetonide binds to intracellular glucocorticoid receptors in retinal cells, forming a complex that translocates to the nucleus and modulates gene transcription. This down‑regulates pro‑inflammatory cytokines, decreases vascular permeability, and inhibits angiogenic factors, thereby reducing fluid accumulation in the macula. The intravitreal implant releases the steroid at a low, constant rate, maintaining therapeutic concentrations in the vitreous cavity for months. By suppressing leukocyte migration and stabilizing cell membranes, the drug further limits retinal damage.

Side Effects

Common Side Effects

  • Increased intraocular pressure: may require topical medication.
  • Cataract formation: gradual lens opacity over time.
  • Ocular pain or discomfort after implantation.
  • Vitreous floaters: perception of moving spots.
  • Conjunctival hemorrhage: minor bleeding on the eye surface.

Serious or Rare Side Effects

  • Endophthalmitis: severe intraocular infection.
  • Retinal detachment: separation of retinal layers.
  • Implant migration: displacement of the device within the eye.
  • Severe ocular hypertension: pressure rise needing surgical intervention.
  • Vision loss: irreversible loss of visual acuity.

Precautions & Warnings

Iluvien requires careful patient assessment and monitoring.

  • Patient selection: evaluate for pre‑existing glaucoma or uncontrolled intraocular pressure.
  • Monitoring: schedule regular intraocular pressure checks after implantation.
  • Contraindications: avoid in eyes with active infection or inflammation.
  • Pregnancy: safety not established; use only if potential benefit outweighs risk.
  • Systemic corticosteroid use: consider additive immunosuppressive effects.
  • Store at ambient temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Iluvien may interact with other ocular or systemic agents.

Major Interactions (Avoid)

  • Other intravitreal corticosteroids: additive pressure rise.
  • Systemic potent CYP3A4 inhibitors: may increase systemic exposure.
  • Active ocular infection: contraindicated during implantation.

Moderate Interactions (Monitor Closely)

  • Topical ocular NSAIDs: increased risk of corneal toxicity.
  • Systemic anticoagulants: monitor for ocular hemorrhage.

Frequently Asked Questions

Iluvien is an intravitreal sustained‑release implant containing fluocinolone acetonide. It is prescribed to treat diabetic macular edema by delivering a corticosteroid directly to the retina, helping to reduce swelling and stabilize vision in adult patients.

Fluocinolone acetonide binds to glucocorticoid receptors inside retinal cells, altering gene transcription. This suppresses inflammatory cytokines, lowers vascular permeability, and inhibits angiogenesis, which together reduce fluid buildup in the macula and improve retinal health.

Iluvien is supplied as a 0.19 mg intravitreal implant. The exact dosing schedule, including the decision to implant and any re‑implantation timing, is determined by the prescribing ophthalmologist based on individual patient needs.

The safety of fluocinolone acetonide implants in pregnancy and lactation has not been established. Use is only considered when the potential benefit to the mother outweighs any possible risk to the fetus or infant.

To request Iluvien, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Iluvien offers a sustained‑release corticosteroid option that can last up to three years, reducing the frequency of injections compared with short‑acting anti‑VEGF agents. It is typically considered when patients have an inadequate response to or cannot tolerate frequent anti‑VEGF therapy.

The Iluvien implant should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect it from moisture and direct light. Do not freeze or expose the device to extreme temperatures before implantation.

Iluvien is implanted by an ophthalmologist using a specialized intravitreal injection technique. The 0.19 mg implant is placed into the vitreous cavity of the eye, where it releases fluocinolone acetonide continuously over several months.

Serious risks include elevated intraocular pressure that may require surgical intervention, cataract formation, endophthalmitis (eye infection), retinal detachment, and possible migration of the implant within the eye. Patients are monitored closely for these events.

Iluvien is contraindicated in patients with active ocular infection, uncontrolled glaucoma, or a history of severe intraocular pressure spikes. It should also be avoided in individuals with known hypersensitivity to fluocinolone acetonide or any component of the implant.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fluocinolone Acetonide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT